Cost-Effectiveness Analysis of Antibiotics in Pneumonia Patients with Diabetes Mellitus Type 2
Downloads
Background: Pneumonia poses a high clinical and economic burden, particularly in patients with type 2 diabetes mellitus (DM). Selecting the appropriate antibiotic is essential to ensure both clinical effectiveness and cost efficiency. This study aimed to evaluate the cost-effectiveness of fluoroquinolone monotherapy compared to beta-lactam–macrolide combination therapy in BPJS inpatients with pneumonia and comorbid type 2 DM at Prof. Dr. Sulianti Saroso Infectious Diseases Hospital (RSPI) during 2023–2024.
Methods: This retrospective observational study used a cost-effectiveness analysis (CEA) approach, drawing on medical record data. Effectiveness was measured based on the Pneumonia Severity Index (PSI) and length of stay, while total direct medical costs were analyzed to calculate the Average Cost-Effectiveness Ratio (ACER).
Results: There was no significant difference in effectiveness or total direct medical costs between the two regimens. However, fluoroquinolone monotherapy had lower total costs (Rp10,090,591) and a smaller ACER value than the beta-lactam–macrolide combination (Rp13,386,045), suggesting that monotherapy was more cost-effective despite similar clinical outcomes.
Conclusion: Although statistical differences were not significant, fluoroquinolone monotherapy appeared more cost-effective than beta-lactam–macrolide combination therapy for pneumonia patients with comorbid type 2 DM. These findings may support pharmacoeconomic-based decision-making in antibiotic selection. The study’s limitations include a small sample size, a single-center setting, and a retrospective design, which may affect generalizability.
Downloads
Lim WS. Pneumonia—Overview. In: Encyclopedia of Respiratory Medicine. Elsevier; 2022. p. 185–97.
Dadonaite B, Roser M. Pneumonia [Internet]. Our World in Data. 2024 [cited 2024 Oct 15]. Available from: https://ourworldindata.org/pneumonia#all-charts
Badan Penelitian dan Pengembangan Kementerian Kesehatan Republik Indonesia. Hasil Utama Riset Kesehatan Dasar Tahun 2018. 2018 Mar.
Kementerian Kesehatan Republik Indonesia, Badan Kebijakan Pembangunan Kesehatan. Survei Kesehatan Indonesia (SKI) 2023. 2023.
Dinas Kesehatan Daerah Istimewa Yogyakarta. Instrumentasi Survei Kesehatan Indonesia 2023 (Riskesdas 2023) [Internet]. https://dinkes.jogjaprov.go.id/. 2023 [cited 2024 Nov 22]. Available from: https://dinkes.jogjaprov.go.id/berita/detail/instrumentasi-survei-kesehatan-indonesia-2023-riskesdas-2023
Rastiti L, Kristina SA, Andayani TM. Analisis Biaya Penyakit Pneumonia pada Pasien Dewasa di Rumah Sakit Cost of Illness Analysis in Pneumonia Among Adult Patients : a Hospital Perspective. Majalah Farmaseutik. 2023 Jan 16;19(4):527–34.
Dewan Jaminan Sosial Nasional, BPJS Kesehatan. Statistik JKN 2015-2019 : Fakta dan Data Capaian Program Jaminan Kesehatan Nasional. 1st ed. Dewan Jaminan Sosial Nasional; 2021.
Cilloniz C, Torres A. Diabetes Mellitus and Pneumococcal Pneumonia. Diagnostics. 2024 Apr 22;14(8):859.
Jensen AV, Egelund GB, Andersen SB, Trier Petersen P, Benfield T, Faurholt-Jepsen D, et al. The impact of blood glucose on community-acquired pneumonia: a retrospective cohort study. ERJ Open Res. 2017 Apr 19;3(2):00114–2016.
Pan S, Zhang Z, Pang W. The causal relationship between bacterial pneumonia and diabetes: a two-sample mendelian randomization study. Islets. 2024 Dec 31;16(1).
Srakocic S, Wood KM. What’s the Connection Between Diabetes and Pneumonia? [Internet]. Healthline. 2022 [cited 2024 Oct 21]. Available from: https://www.healthline.com/health/pneumonia/whats-the-connection-between-diabetes-and-pneumonia#pneumonia-prevention
Kementerian Kesehatan RI. Peraturan Menteri Kesehatan Republik Indonesia Nomor 28 Tahun 2021 Tentang Pedoman Penggunaan Antibiotik. Kementerian Kesehatan Republik Indonesia, 1116, 2021 Indonesia; 2021.
Kementerian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Pneumonia Pada Dewasa. Kementerian Kesehatan Republik Indonesia, HK.01.07/MENKES/2147/2023 Indonesia: jdih.kemenkes.go.id; Nov 21, 2023.
Pancu DF, Scurtu A, Macasoi IG, Marti D, Mioc M, Soica C, et al. Antibiotics: Conventional Therapy and Natural Compounds with Antibacterial Activity—A Pharmaco-Toxicological Screening. Antibiotics. 2021 Apr 7;10(4):401.
Allel K, Hernández-Leal MJ, Naylor NR, Undurraga EA, Abou Jaoude GJ, Bhandari P, et al. Costs-effectiveness and cost components of pharmaceutical and non-pharmaceutical interventions affecting antibiotic resistance outcomes in hospital patients: a systematic literature review. BMJ Glob Health. 2024 Feb 29;9(2):e013205.
Mahendrakar A, Ajja H, Sinwal A, . I, . N, Jain P. Pharmacoeconomics in Healthcare By IJISRT. International Journal of Innovative Science and Research Technology (IJISRT). 2024 Mar 26;1102–7.
Maharani L, Utami ED, Mustikaningtias I, Suryoputri MW, Samodro P. Pengaruh Konversi Antibiotik Intravena ke Rute Per-oral terhadap Outcome Ekonomi, Klinis dan Humanis pada Pasien Rawat Inap. Indonesian Journal of Clinical Pharmacy. 2019 Jun 28;8(2):81.
Shrestha J, Zahra F, Cannady Jr. P. Antimicrobial Stewardship [Internet]. National Library of Medicine - National Center for Biotechnology Information. 2023 [cited 2024 Nov 22]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572068/
Ceccato A, Cilloniz C, Martin-Loeches I, Ranzani OT, Gabarrus A, Bueno L, et al. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia. Chest. 2019 Apr;155(4):795–804.
Han X, Chen L, Wang Y, Li H, Wang H, Xing X, et al. Cost Effectiveness of Different Initial Antimicrobial Regimens for Elderly Community-Acquired Pneumonia Patients in General Ward. Infect Drug Resist. 2021 May;Volume 14:1845–53.
Choi SH, Cesar A, Snow TAC, Saleem N, Arulkumaran N, Singer M. Respiratory fluoroquinolone monotherapy vs. β-lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials. Int J Antimicrob Agents. 2023 Sep;62(3):106905.
Fahreza F, Novita D, Meutia S. A 56 Years Old Female with Uncontrolled Diabetes Mellitus Type II, Pneumonia, and Suspect With Lung Abscess: a Case Report. Jurnal Kedokteran Diponegoro (Diponegoro Medical Journal). 2023 Aug 31;12(5):322–5.
Rahardjoputro R, Amrullah AW, Santoso J, Saraswati HAC, Ernawati, Astuti HP, et al. Cost-Consequence Analysis of Levofloxacin Compared to Ceftriaxone in Community-Acquired Pneumonia of Adult Inpatients at X Hospital Surakarta. JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA. 2024 Apr 30;11(1):89–100.
Nathala P, Sarai S, Salunkhe V, Tella MA, Furmanek SP, Arnold FW. Comparing Outcomes for Community-Acquired Pneumonia Between Females and Males: Results from the University of Louisville Pneumonia Study. Univ Louisville J Respir Infect. 2022 Aug 11;6(1).
Webber T, Ronacher K, Conradie-Smit M, Kleynhans L. Interplay Between the Immune and Endocrine Systems in the Lung: Implications for TB Susceptibility. Front Immunol. 2022 Feb 22;13.
Kim NH, Sim SJ, Han HG, Yoon JH, Han YH. Immunosenescence and age-related immune cells: causes of age-related diseases. Arch Pharm Res. 2025 Feb 26;48(2):132–49.
Perhimpunan Dokter Paru Indonesia. Pedoman Diagnosis dan Penatalaksanaan di Indonesia Pneumonia Komunitas. 2nd ed. Burhan E, Isbaniah F, Hatim F, Djaharuddin I, Soedarsono, Harsini, et al., editors. Jakarta: Perhimpunan Dokter Paru Indonesia; 2022.
Lai C, Ma Z, Zhang J, Wang J, Wang J, Wu Z, et al. Efficiency of combination therapy versus monotherapy for the treatment of infections due to carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis. Syst Rev. 2024 Dec 19;13(1):309.
Holland P, Jahnke N. Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis. Cochrane Database of Systematic Reviews. 2021 Jun 23;2021(6).
Arifah G, Halimah E, Abdulah R. Comparison of Effectiveness between Combination of Beta-Lactam with Azyhtromycin or Levofloxacin for Adult Pneumonia Patients. Pharmacology and Clinical Pharmacy Research. 2018 Apr 23;3(1).
Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 Diabetes and its Impact on the Immune System. Curr Diabetes Rev. 2020 May 12;16(5):442–9.
PERKENI. Pedoman Terapi Insulin Pada Pasien Diabetes Melitus 2019. Jakarta: Perkumpulan Endokrinologi Indonesia; 2019.
Rusli R, Nurisyah N, Dewi R, Rianti AE, Khafifah K. Kesesuaian Penggunaan Obat Pada Pasien Diabetes Melitus Berdasarkan Algoritma Terapi Di Wilayah Kerja Puskesmas Andalas Dan Puskesmas Tarakan Kota Makassar. Jurnal Media Analis Kesehatan [Internet]. 2024 Dec 14;15(2):112–23. Available from: https://ojs3.poltekkes-mks.ac.id/index.php/medankes/article/view/1074
Lüthi-Corridori G, Boesing M, Roth A, Giezendanner S, Leuppi-Taegtmeyer AB, Schuetz P, et al. Predictors of Length of Stay, Rehospitalization and Mortality in Community-Acquired Pneumonia Patients: A Retrospective Cohort Study. J Clin Med. 2023 Aug 28;12(17):5601.
Uematsu H, Yamashita K, Kunisawa S, Imanaka Y. Prediction model for prolonged length of stay in patients with community-acquired pneumonia based on Japanese administrative data. Respir Investig. 2021 Mar 1;59(2):194–203.
Bader MS, Yi Y, Abouchehade K, Haroon B, Bishop LD, Hawboldt J. Community-Acquired Pneumonia in Patients With Diabetes Mellitus: Predictors of Complications and Length of Hospital Stay. Am J Med Sci. 2016 Jul;352(1):30–5.
Kilbert B, Kehr A, David Lim SY, Kalathia J, Khaliq R, Hostoffer R. Effect of OMT on Hospital Length of Stay in Elderly Patients with Pneumonia: A Meta-Analysis. Scholar: Pilot and Validation Studies. 2022 Jul 1;3(1):5–9.
Irawan R, Reviono, Harsini. Korelasi Kadar Copeptin dan Skor PSI dengan Waktu Terapi Sulih Antibiotik Intravena ke Oral dan Lama Rawat Pneumonia Komunitas. Jurnal Respirologi Indonesia. 2019;39(1):44–53.
Yuskawati D, Astuty DA, Wahyudi W. Faktor-Faktor yang Berhubungan dengan Length of Stay Pasien Pneumonia di Rumah Sakit Umum Haji Medan. MAHESA : Malahayati Health Student Journal. 2024 May 1;4(5):1649–64.
Perhimpunan Dokter Paru Indonesia. Panduan Umum Praktis Klinis Penyakit Paru dan Pernafasan. 1st ed. Kosasih A, Sutanto YS, Susanto AD, editors. Jakarta: Perhimpunan Dokter Paru Indonesia; 2021.
Fitrotul Jannah A, Dewi O, Abidin Z. Perbandingan Efektivitas Antibiotik Golongan Sefalosporin Dan Golongan Kuinolon Pada Pasien Rawat Inap Infeksi Saluran Kemih Di RSUD Kota Madiun. Vol. 11, Jurnal Ilmiah Farmasi. 2022.
Xu LY, Wang CC, Peng XX, Jiao Y, Zhao CZ, Zhang L, et al. Empirical antibiotic treatment strategies for community-acquired pneumonia: a network meta-analysis. J Glob Antimicrob Resist. 2022 Sep;30:1–9.
Efriani L, Putra TA, Fitriyani F. Analisis efektivitas antibiotik levofloxacin dan ceftriaxon pada pasien pneumonia di instalasi rawat inap RSD X Kota Cirebon Tahun 2023. Journal of Pharmaceutical and Sciences. 2025 Mar 18;564–70.
Haris BB, Puspitasari CE, Andanalusia M, Saputra YD. Perbandingan Efikasi Klinis Terapi Antibiotik dan Biaya Langsung Medis Pasien Pneumonia Komunitas di Instalasi Rawat Inap RSUD Provinsi NTB Tahun 2021 [Skripsi]. [Mataram]: Universitas Mataram; 2022.
Aoralia S. Cost Effectiveness Analysis Penggunaan Antibiotik Levofloxacin dan Ceftriaxone Untuk Mengatasi Penyakit Pneumonia di Instalasi Rawat Inap di Rumah Sakit Islam Sultan Agung Semarang. [Semarang]: Universitas Islam Sultan Agung Semarang; 2022.
Nurjahan, Rahayuningsih N, Idacahyati K. Cost-Effectiveness Analysis Terapi Antibiotik pada Pasien Infeksi Saluran Kemih di Rumah Sakit. Jurnal Farmasi Klinik Indonesia [Internet]. 2024;13(3):171–82. Available from: http://ijcp.or.id
Syahniar R, Akbar MA, Kharisma DS, Nabila AN. Comparison Between Monotherapy and Combination Therapy Among Inpatients with Community-Acquired Pneumonia. Jurnal Ilmiah Farmasi (Scientific Journal of Pharmacy). 2021 Jun;17(1):56–63.
Fitri Fatkhiya M, Perwitasari DA, Febriana SA. Analisis Biaya Sakit Perspektif Masyarakat Pada Penderita DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) di RSUP Dr. Sardjito Yogyakarta. Media Farmasi. 2020 Mar;17(1):49–59.
Copyright (c) 2025 The Indonesian Journal of Infectious Diseases
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
